Cargando…
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with re...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984267/ https://www.ncbi.nlm.nih.gov/pubmed/24734215 http://dx.doi.org/10.4161/onci.27482 |